Oncolytics Biotech Announces Additional Positive Phase 2 REOLSYIN Clinical Trial Data
February 08, 2013 at 06:52 AM EST
Oncolytics Biotech (NASDAQ: ONCY ) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best
